Simple Summary Oligometastatic disease is a condition in oncology where cancer affects
only a few distant sites. It is associated with a low-burden spread and a more favorable …

With the improved understanding of driver mutations in non-small cell lung cancer (NSCLC),
expanding the targeted therapeutic options improved the survival and safety. However …

Background: Lung adenocarcinoma (LUAD) is one of the most lethal malignancies and is
currently lacking in effective biomarkers to assist in diagnosis and therapy. The aim of this …

Background The understanding of the factors causing decreased overall survival (OS) in
older patients compared to younger patients in lung adenocarcinoma (LUAD) remains …

Background Multidrug resistance is the biggest barrier on the way to chemotherapy for lung
adenocarcinoma (LUAD). For some LUAD patients with cisplatin (DDP) resistance and poor …

Lung cancer, being the most widespread and lethal form of cancer globally, has a high
incidence and mortality rate primarily attributed to challenges associated with early …

Background APOBEC family play an important role in cancer mutagenesis and tumor
development. The role of APOBEC family in lung adenocarcinoma (LUAD) has not been …

Simple Summary Receptor tyrosine kinases are present on the cell membrane of some cell
types and are responsible for the regulation of cell growth. These receptors are frequently …

Aim: To find biomarkers for immunity and immunotherapy in lung adenocarcinoma (LUAD)
through multiomics analysis. Materials & methods: The multiomics data of patients with …

Background Immunotherapy has had a high success rate in treating lung adenocarcinoma
(LUAD) for several decades. However, many patients do not benefit from immunotherapy …